Secondly, the drug should be able to spare beneficial CD25 positive cells (e.g. activated NK cells, activated tumor specific CD8 T cells) whilst eliminating unwanted CD25 positive cells (e.g. Treg, CD25+ AML blasts). This evidence concerns the gene IL2RA and acute myeloid leukemia.